Pre- and postoperative chemotherapy including Bevacizumab in potentially curable metastatic colorectal Cancer (mCRC). A multicenter, prospective Phase I/II academic trial.

primary objective: Resectability (R0) rate after neoadjuvant XELOX+Avastin in potentially resectable mCRC primary objective: Resectability (R0) rate after neoadjuvant Avastin in potentially resectable mCRCsecondary objectives: Feasibility with regards to GI bleeding and wound healing complications after surgery of liver metastases, general safety, ORR, RFS, OS